Back to search results
NCT07228403

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
Zealand Pharma
~28 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:Glepaglutide 10 mg

At a glance

Recruiting sites
0 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of treatment emergent adverse events (TEAEs)
Measured over From baseline to the safety follow-up visit (A maximum of 25 months)

Conditions

Short Bowel Syndrome (SBS)

Explore related trials

Short Bowel Syndrome

NCT07228403

Where you'd take part

This study runs at 16 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AP-HP - Hôpital Beaujon

    Clichy, Hauts-de-Seine, Franceno site contact published

  • Asklepios Klinik St. Georg

    Hamburg, Germanyno site contact published

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, Germanyno site contact published

  • Cleveland Clinic-9500 Euclid Ave

    Cleveland, Ohiono site contact published

  • LHSC - University Hospital

    London, Ontario, Canadano site contact published

  • Lied Transplant Center at Nebraska Medical Center

    Omaha, Nebraskano site contact published

  • Mayo Clinic - PPDS

    Rochester, Minnesotano site contact published

  • Samodzielny Publiczny Szpitala Kliniczny im. Prof. Witolda Orlowskiego CMKP

    Warsaw, Masovian Voivodeship, Polandno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has provided signed informed consent and agrees to comply with protocol requirements.
Is being

Exclusion

Has a condition, disease, or circumstance that, in the opinion of the investigator, would put the patient at any undue risk, prevent completion of the trial, or confound the planned assessments of the trial.
Use of GLP-1, GLP-2 (e.g., teduglutide), HGH, DPP-4 inhibitors, somatostatin, or analogs thereof. Note: Prior use of glepaglutide is allowed.
Had major protocol deviation(s) (as determined by the sponsor) in the EASE SBS 2 or EASE SBS 3 trial that would affect the conduct of the present trial.
Has permanently discontinued the trial treatment because of an AE, assessed as related to the trial drug in the EASE SBS 2 or EASE SBS 3 trial. (Note: AEs are treatment-emergent unless otherwise specified.)
If female, is of childbearing potential, pregnant, breastfeeding, intends to become pregnant, or is not using contraceptive methods. Refer to Section 10.2.2 for the definition of contraception.
Has a known or suspected hypersensitivity to glepaglutide or related products.
Has committed to an institution by virtue of an order issued by the judicial or administrative authorities.
Is an employee of the sponsor or investigator or otherwise dependent on them.

What this trial measures

  • Number of treatment emergent adverse events (TEAEs)From baseline to the safety follow-up visit (A maximum of 25 months)